Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.
Catherine M ViscoliKieran F DochertyLars KøberMikhail Naum KosiborodFelipe A MartinezPiotr PonikowskiMarc S SabatineScott D SolomonSubodh VermaJan BělohlávekMichael BöhmChern-En ChiangRudolf A de BoerMirta DiezAndre DukátCharlotta E A LjungmanOlof BengtssonAnna Maria LangkildeMikaela SjöstrandPardeep S JhundJohn Joseph Valentine McMurraynull nullPublished in: Diabetes care (2020)
In this exploratory analysis among patients with HFrEF, treatment with dapagliflozin reduced the incidence of new diabetes. This potential benefit needs confirmation in trials of longer duration and in people without heart failure.